Overview

Juno Therapeutics is a clinical-stage company developing novel cellular immunotherapies based on two distinct and complementary platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Our goal is to revolutionize medicine by re-engaging the body’s immune system to treat cancer.

Juno Therapeutics Adds Next-Generation Single Cell Sequencing Capabilities Through Acquisition of AbVitro

The acquisition provides Juno with a leading next-generation single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T-cells. AbVitro’s technology allows for the identification of fully-human, natively paired T-cell receptors (TCRs) and chimeric antigen receptors (CAR) T binders directly from patients. This capability, which allows for the interrogation of millions of single cells per experiment, enables the rapid generation of binders that recognize known targets, as well as the discovery of novel antigen targets in both cancer and autoimmunity. The AbVitro platform enables immediate acceleration of Juno’s efforts to identify and develop new targets in solid tumors. Juno will also use this technology for translational assays to provide a better understanding of the natural immune response to cancer, as well as to interrogate and monitor the immune system of cancer patients during treatment.

The acquisition of this transformational technology extends Juno’s leadership in the research and development of CAR-T and TCR based therapies by providing Juno with a leading next-generation, single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T-cells.

Our Science

The use of human T cells as therapeutics to re-engage the immune system has the potential to revolutionize the way cancer is treated. Juno’s technologies genetically engineer a patient’s own T cells to recognize and kill cancer cells. These cellular therapies have the potential to be effective regardless of the type of previous treatments patients have experienced and may avoid the long-term side effects associated with current treatments. We use two different technologies to target cancer cells and activate T cells, CARs and TCRs.

Chimeric Antigen Receptors (CARs)

Chimeric Antigen Receptor (CAR) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins.

T Cell Receptors (TCRs)

High-affinity TCR technology provides T cells with a specific T cell receptor that recognizes cancer cells based on expression of specific proteins inside the cell or on the cell surface.

For Patients

T cell immunotherapy using CAR and TCR technologies have shown promising results in early clinical trials and may offer new options for patients with cancer.